4See Ventures

4See Ventures is a Swiss venture capital firm established in 2019 and based in Geneva. The firm specializes in investing in exceptional entrepreneurs who are poised to redefine their industries, with a particular focus on healthcare, biotechnology, medical technology, technology, sustainability, and climate technology. By targeting game-changing ventures, 4See Ventures aims to support companies that have a positive impact on society, primarily within Switzerland.

Daniel Bertholet

Founder and Managing Partner

4 past transactions

HAYA Therapeutics

Seed Round in 2022
HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other serious age-related conditions. The company specializes in precision pharmaceuticals, creating innovative genetic treatments that are selectively targeted to specific tissues and cells. HAYA Therapeutics employs a discovery engine that identifies tissue- and cell-specific drivers of fibrosis and other disease processes by leveraging non-coding RNAs in the human genome. Through its biopharmaceutical therapies, HAYA Therapeutics seeks to block myocardial fibrosis, offering potential new options for the management of heart failure and related disorders.

CYSEC

Seed Round in 2022
CYSEC is a startup working on next generation Confidential Computing solutions securing data at rest, in motion and in use. Currently they have released their ARCA solution which is quickly becoming one of the more popular choices in the market.

HAYA Therapeutics

Seed Round in 2021
HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other serious age-related conditions. The company specializes in precision pharmaceuticals, creating innovative genetic treatments that are selectively targeted to specific tissues and cells. HAYA Therapeutics employs a discovery engine that identifies tissue- and cell-specific drivers of fibrosis and other disease processes by leveraging non-coding RNAs in the human genome. Through its biopharmaceutical therapies, HAYA Therapeutics seeks to block myocardial fibrosis, offering potential new options for the management of heart failure and related disorders.

keepMED

Series C in 2020
keepMED develops a device for treatment of Obstructive Sleep Apnea, a disorder characterized by repetitive episodes of upper airway obstruction that occur during sleep.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.